ClinicalTrials.gg
Active, not recruitingNCT05930561Updated Aug 21, 2026

4D-150 in Patients With Diabetic Macular Edema

A Phase 2 interventional study of 4D-150 IVT and Aflibercept IVT in Diabetic Macular Edema and Diabetic Retinopathy, sponsored by 4D Molecular Therapeutics. Active, not recruiting at 6 sites in 2 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-08-21.

Sponsored by 4D Molecular Therapeutics · Phase 2, Interventional, and Treatment

How we know

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
72
Allocation
Non-randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 267 studies in Diabetic Retinopathy with a site in United States — 36 open to participants now, 54 under way, 6 of them phase 3. Diabetic Retinopathy · United States.

Planned enrollment
98th of 196
72 · median 72
Started
2023
with 11 others
Phase 2
52 of 267
3 open now
Primary completion
2029-02
later than 42 of 52 live
Registered
220th of 267
by date

Among the 267 studies in Diabetic Retinopathy with a site in United States, this one is the 98th largest by planned enrollment of the 196 interventional ones that give a count, is one of 12 that started in 2023, is one of 52 in phase 2, reaches primary completion later than 42 of the 52 other live ones, and was the 220th registered.

Diabetic Retinopathy

783 studies on the registry are indexed under Diabetic Retinopathy; 145 are open to participants now.

Browse Diabetic Retinopathy studies →

Open to participants now

36 of the 267 studies in Diabetic Retinopathy with a site in United States are open now. Recruiting first, the newest first:

31 more — sign in →

All 36 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 93 Diabetic Retinopathy studies recruiting now, 61 (66%) set no upper age limit and 10 (11%) stop at 75 or younger; 8 take children under 18; 30 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 267 studies in Diabetic Retinopathy with a site in United States, or all of them as a file.
02

Study summary

Phase 2 randomized, active-controlled, double-masked, dose-ranging trial in adults with Diabetic Macular Edema (DME).

Read the detailed description

This Phase 2 trial is a prospective, multicenter, randomized, active-controlled, double-masked dose-ranging trial to evaluate the safety and efficacy of 4D-150 in adults with DME. The trial will be conducted in two parts: Dose Confirmation and Dose Expansion.

03

Conditions studied

  • Diabetic Macular Edema
  • Diabetic Retinopathy

Browse trials for

Keywords

  • Retinal gene therapy
  • Intravitreal gene therapy
  • DME
  • SPECTRA
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • ≥18 years of age
  • Type I or Type II diabetes mellitus with macular thickening secondary to DME involving the center of the fovea; diagnosis of DME must be within 2 years of Screening
  • CST ≥ 350 μm (Spectralis SD-OCT) in the study eye at Screening, confirmed by the independent reading center
  • Demonstrate clinical response to on-study aflibercept injection in the study eye.
  • Decreased visual acuity attributable primarily to DME
  • BCVA in the study eye between 25 and 83 ETDRS letters, inclusive (\~20/320 and 20/25, respectively) at Screening
  • Study eye amenable to IVT injection
  • Sufficient clear ocular media, pupil dilation and fixation in the study eye to permit adequate imaging; ability to perform tests of visual and retinal function and structure; and ability to comply with other protocol-specified procedures
  • Provide written

Exclusion criteria

Exclusion Criteria:

  • Macular edema in the study eye considered to be secondary to a cause other than DME
  • Systemic anti-VEGF treatment (e.g. sunitinib, bevacizumab, pazopanib) within 6 months, or anticipated need for systemic anti-VEGF therapy during study participation
  • Systemic (oral, intravenous, intramuscular, intra-articular) or other medications within 3 months
  • Received an drug, agent, device, or therapy (ocular or non-ocular) in the 3 months (or at least 5 half-lives, whichever is longer) prior to 4D-150 administration (Day 1)
  • Prior gene therapy (ocular or non-ocular) and/or ocular stem cell therapy in either eye
  • Any concurrent ocular condition in the study eye that is likely to require surgical intervention (e.g. cataract surgery) during the 2 year (104 week) study duration

Note: Other inclusion/exclusion criteria apply.

Terms in these criteria, in plain language(4)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Non-randomized
Intervention model
Parallel assignment
Masking
Double (Participant, Outcomes assessor)
Enrollment
72 participants (estimated)

Study arms

  • Experimental
    4D-150 Part 1 Dose Confirmation Dose Level 1

    4D-150 will be administered at the assigned dose level as a single dose IVT injection on Day 1.

    Biological: 4D-150 IVT

  • Experimental
    4D-150 Part 1 Dose Confirmation Dose Level 2

    4D-150 will be administered at the assigned dose level as a single dose IVT injection on Day 1.

    Biological: 4D-150 IVT

  • Experimental
    4D-150 Part 2 Dose Expansion Dose Level 1

    4D-150 will be administered at the assigned dose level as a single dose IVT injection on Day 1.

    Biological: 4D-150 IVT

  • Experimental
    4D-150 Part 2 Dose Expansion Dose Level 2

    4D-150 will be administered at the assigned dose level as a single dose IVT injection on Day 1.

    Biological: 4D-150 IVT

  • Active comparator
    4D-150 Part 2 Dose Expansion Control

    Aflibercept at a fixed regimen will be administered.

    Biological: Aflibercept IVT

Interventions

  • Biological4D-150 IVT

    4D-150: AAV-based gene therapy comprised of miRNA targeting VEGF-C and codon-optimized sequence encoding aflibercept.

  • BiologicalAfliberceptStudies of AfliberceptAflibercept pageHow we knowJudged by ClinicalTrials.gg, not part of the registry record.

    Commercially available Active Comparator

    Also known as: Eylea

06

What researchers measure

Primary outcomes

  1. Incidence and severity of TEAEs and SAEs, including clinically significant changes in safety parameters (Part 1)

    Time frame: 60 months

  2. Annualized number of aflibercept injections in the study eye (Part 2)

    Time frame: 52 weeks

Secondary outcomes

  1. Mean cumulative number of aflibercept injections over time

    Time frame: 52 weeks

  2. Change from baseline in BCVA as assessed using the ETDRS Visual Acuity Chart at Weeks 52 and 104

    Time frame: 104 weeks

  3. Change from baseline in CST measured by spectral domain optical coherence tomography (SD-OCT) at Weeks 104

    Time frame: 104 weeks

Other outcomes

  1. Incidence and severity of treatment-emergent adverse events and serious adverse events, including clinically significant changes in safety parameters

    Time frame: 104 weeks

  2. Development of anti-drug antibodies to capsid protein (4D-R100) and the transgene product (aflibercept) and change in antibody titers in subjects receiving 4D-150

    Time frame: 104 weeks

  3. Change in levels of aflibercept protein in aqueous humor and serum overtime

    Time frame: 104 weeks

07

Study locations

6 sites
08

References and documents

Publications

  • Calton MA, Croze RH, Burns C, Beliakoff G, Vazin T, Szymanski P, Schmitt C, Klein A, Leong M, Quezada M, Holt J, Bolender G, Barglow K, Khoday D, Mason T, Delaria K, Hassanipour M, Kotterman M, Khanani AM, Schaffer D, Francis P, Kirn D. Design and Characterization of a Novel Intravitreal Dual-Transgene Genetic Medicine for Neovascular Retinopathies. Invest Ophthalmol Vis Sci. 2024 Dec 2;65(14):1. doi: 10.1167/iovs.65.14.1. PubMed 39620832 ↗
09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Aug 2023 (actual). Primary completion is estimated for Feb 2029, 66 months after the start.

Of 30 industry-sponsored phase 2 interventional studies under Diabetic Retinopathy, half reached primary completion within 30 months of starting (the median), counting those still running; a quarter within 16 and three quarters within 37. This study's planned 66 months is above that.

Counting every sponsor, half of 43 studies reached it within 31 months; a quarter within 17 and three quarters within 37.

How these figures are worked out, and which studies are left out of them.

Registered
Jun 26, 2023
First posted
Jul 5, 2023
StartActual
Aug 9, 2023
Primary completionEst.
Feb 28, 2029
CompletionEst.
Feb 28, 2029
Last update
Aug 21, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Aug 21, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT05930561
Lead sponsor
4D Molecular Therapeutics
Responsible party
Sponsor
First posted
Jul 5, 2023
Start date
Aug 9, 2023
Primary completion
Feb 28, 2029 (estimated)
Completion
Feb 28, 2029 (estimated)
Last update
Aug 21, 2026

Study contacts

Julie Clark, MD
study director · 4D Molecular Therapeutics

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is active, not recruiting, as verified in Aug 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion